ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.5123C>T (p.Ala1708Val) (rs28897696)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000048803 SCV000076816 uncertain significance Hereditary breast and ovarian cancer syndrome 2020-01-07 criteria provided, single submitter clinical testing This sequence change replaces alanine with valine at codon 1708 of the BRCA1 protein (p.Ala1708Val). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and valine. This variant is present in population databases (rs28897696, ExAC 0.04%). This variant has been reported in individuals with a personal and/or family history of breast cancer (PMID: 16489001, 18036263, 22034289, 26287763, 27495310), and an individual affected with kidney cancer (PMID: 26689913). In addition, it has been found in an individual with ovarian cancer (Invitae). However, in that individual a pathogenic allele was also identified in BRCA2, which suggests that this c.5123C>T variant was not the primary cause of disease. This variant is also known as 5242C>T (A1708V) in the literature. ClinVar contains an entry for this variant (Variation ID: 37640). Experimental studies have shown conflicting results for the effect of this missense change on BRCA1 structure and function. This variant caused decreased stability and compromised transcriptional activation, phosphopeptide binding (PMID: 20516115), and homology-directed repair activity (PMID: 26689913). However, in a different study, a protein with this missense variant showed normal stability and a relatively smaller decrease in transcriptional activity (PMID: 18036263). Additionally, a study utilizing a saturation genome editing (SGE) method has reported that this variant does not substantially affect BRCA1 protein function (PMID: 30209399). A different missense substitution at this codon (p.Ala1708Glu) has been determined to be pathogenic (PMID: 1157798, 11802208, 15923272, 19404736, 23867111). This suggests that the alanine residue is critical for BRCA1 protein function and that other missense substitutions at this position may also be pathogenic. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000131166 SCV000186111 uncertain significance Hereditary cancer-predisposing syndrome 2019-01-11 criteria provided, single submitter clinical testing Conflicting evidence
GeneDx RCV000589633 SCV000210201 uncertain significance not provided 2017-12-06 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.5123C>T at the cDNA level, p.Ala1708Val (A1708V) at the protein level, and results in the change of an Alanine to a Valine (GCG>GTG). Using alternate nomenclature, this variant has been previously published as BRCA1 5242C>T. BRCA1 Ala1708Val has been observed in several individuals with a personal and/or family history of breast cancer and in an individual with renal cancer (Chenevix-Trench 2006, Fackenthal 2012, Lu 2015, Pal 2015), but was also present in large cohorts of control individuals undergoing whole exome sequencing (Dorschner 2013, Amendola 2015). In vitro functional studies have reported mixed results for BRCA1 Ala1708Val. Although some studies demonstrate a severe folding defect, compromised binding activity and specificity, diminished homologous recombination repair activity, and decreased transcriptional activation as compared to wild type, others have reported intermediate transcriptional activation and normal foci formation in response to DNA damage (Lovelock 2007, Lee 2010, Lu 2015). Lovelock et al. (2007) suggest that BRCA1 Ala1708Val may represent a pathogenic variant with reduced penetrance. BRCA1 Ala1708Val was not observed at a significant allele frequency in large population cohorts (Lek 2016). BRCA1 Ala1708Val is located in the BRCT 1 domain and a region known to interact with multiple other proteins (UniProt, Paul 2014) . In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Based on currently available evidence, it is unclear whether BRCA1 Ala1708Val is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000212194 SCV000494396 uncertain significance not specified 2019-04-15 criteria provided, single submitter clinical testing Variant summary: BRCA1 c.5123C>T (p.Ala1708Val) results in a non-conservative amino acid change located in the BRCT domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251672 control chromosomes (gnomAD and one publication). The variant, c.5123C>T, has been reported in the literature in individuals affected with cancers (Chenevix-Trench_2006, Fackenthal_2012, Lovelock_2007, Caldes_2002, Pal_2015, Lu_2015, Jarhelle_2016). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. This variant was reported in FLOSSIES database and co-occurrences with another pathogenic variant have been reported in ClinVar (not specified), providing supporting evidence for a benign role. Functional studies showed that this variant leads to varied effects depending upon types of assays performed (Lovelock_2007, Lee_2008, Lu_2015). The variant had normal effect on protein expression and foci formation in response to DNA damage but had intermediate to strong effect on transcription, protein folding, centrosome amplification and phosphopeptide binding. The possibility of the variant to be a mild causative mutation associated with a late onset of the disease cannot be ruled out. Another missense change at the same residue A1708E is a known pathogenic variant; while A1708E leads to charge change, A1708V does not. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000048803 SCV000591584 uncertain significance Hereditary breast and ovarian cancer syndrome 2015-03-27 criteria provided, single submitter clinical testing
Color RCV000131166 SCV000688538 uncertain significance Hereditary cancer-predisposing syndrome 2019-11-12 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000589633 SCV001133610 uncertain significance not provided 2019-08-15 criteria provided, single submitter clinical testing
Institute of Human Genetics, University of Leipzig Medical Center RCV001253393 SCV001429075 uncertain significance Deafness, autosomal dominant 13 2018-07-09 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000031221 SCV000053821 uncertain significance Breast-ovarian cancer, familial 1 2012-05-01 no assertion criteria provided clinical testing
CSER _CC_NCGL, University of Washington RCV000148393 SCV000190092 uncertain significance Breast and/or ovarian cancer 2014-06-01 no assertion criteria provided research
Department of Medical Genetics, University Hospital of North Norway RCV000031221 SCV000301438 uncertain significance Breast-ovarian cancer, familial 1 2016-05-01 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory,Women's College Hospital, University of Toronto RCV000212194 SCV000587467 uncertain significance not specified 2014-01-31 no assertion criteria provided research
Clinical Genomics Lab,St. Jude Children's Research Hospital RCV000761087 SCV000891002 uncertain significance Craniopharyngioma 2016-11-15 no assertion criteria provided clinical testing
Brotman Baty Institute,University of Washington RCV000031221 SCV001242169 not provided Breast-ovarian cancer, familial 1 no assertion provided in vitro

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.